Jin-Ho Park

Jin-Ho Park

Auto-generated profile, based on publicly available information

Jin-Ho Park

Center For Systems Biology Harvard Medical School Massachusetts General Hospital Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
MAMarylyn Setsuko Arai
Marylyn Setsuko Arai
HKHyunho Kim
Hyunho Kim
MPMadeleine Pascavis
Madeleine Pascavis
BCBaekdong Cha
Baekdong Cha
GBGabriel Brambilla
Gabriel Brambilla
HLHakho Lee
Hakho Lee

13 March 2025 in ACS Applied Nano Materials
Verified
Journal Article
Closed access
JPJin-Ho Park
Jin-Ho Park
KNKyeonghyeon Nam
Kyeonghyeon Nam
YCYoung Kwan Cho
Young Kwan Cho
MAMarylyn Setsuko Arai
Marylyn Setsuko Arai
Dong-Hwan KimDong-Hwan Kim
Dong-Hwan Kim
HLHakho Lee
Hakho Lee

18 August 2026 in Small
Verified
Journal Article
Closed access
PDF file
JPJin‐Ho Park
Jin‐Ho Park
YCYoung Kwan Cho
Young Kwan Cho
VSVicki Schaal
Vicki Schaal
DJDae‐Han Jung
Dae‐Han Jung
MCMoonhyun Choi
Moonhyun Choi
HLHakho Lee
Hakho Lee

1 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SSSudeep Sarma
Sudeep Sarma
YCYoung Kwan Cho
Young Kwan Cho
ATArpan Tapdiya
Arpan Tapdiya
JPJin-Ho Park
Jin-Ho Park
HLHakho Lee
Hakho Lee
CHCarol K. Hall
Carol K. Hall
Assays for cancer diagnosis via the analysis of tumor biomarkers on circulating extracellular vesicles (EVs) have shown great potential. Single EV imaging that can measure the abundance of protein biomarkers in EVs can help in detecting the presence, stage, and progression of disease. Antibodies are typically used to detect EV proteins. Controlling the quality of antibody-based immunoassays can, however, be challenging, as they may exhibit unintended cross-reactivity with non-target proteins or variability in binding affinity across different batches, even for monoclonal antibodies. Here, we report short peptides that are a promising alternative to antibodies for detecting protein biomarkers in EVs. We describe an effort that combines a Pep tide B inding D esign (PepBD) algorithm and molecular-level simulations to identify peptides that can recognize (1) the extracellular domain of EpCAM (a known cancer biomarker) and (2) the extracellular domain of tetraspanin CD81(a protein commonly expressed on the surface of EVs). The peptides designed for EpCAM and CD81 were labeled with a fluorescent dye and their binding to the target protein was evaluated using fluorescence ELISA. The results demonstrated that one of the computationally designed peptides EP-2.1 exhibited an affinity for the target EpCAM protein comparable to that of an antibody. Further testing involved single EV imaging to gauge the peptide’s affinity towards EVs. Designed peptides for both the target proteins showed similar affinity as antibodies to EVs.